BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Neutral 52.5%

Neg 0% Neu 52.5% Pos 0%

BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.